Retinoblastoma is the most common intraocular malignancy afflicting children. Among children less than five years of age, retinoblastoma represents 6.1% of all cancers. Retinoblastoma treatment, as a market, is currently untapped due to limited treatment options, devastating effects, and small patient population. R&D in this field will allow major companies involved to capitalize on the market.
Global Retinoblastoma Treatment - Market Dynamics
The report details several factors driving and restraining the market, some of which are discussed below.
Remission and the chance of recurrence
Increasing public awareness
Small patient pool
Stringent regulatory guidelines
The global retinoblastoma treatment market has been segmented by type of treatment into surgery, radiation therapy, photocoagulation, cryotherapy, thermotherapy, chemotherapy (carboplatin, cisplatin, vincristine, etoposide, cyclophosphamide, topotecan, doxorubicin) and high-Dose chemotherapy. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.
Major Companies in the Sector Include:
This Report Offers:
Market definition, along with identification of key drivers and restraints for the market.
Market analysis with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. RESEARCH METHODOLOGY
2.2 Analysis Methodology
2.3 Study Timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW AND INDUSTRY TRENDS
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porters Five Force Analysis
5.3.1 Bargaining Power Of Suppliers
5.3.2 Bargaining Power Of Buyers
5.3.3 Degree Of Competition
5.3.4 Threat Of Substitution
5.3.5 Threat Of New Entrants
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 Market Drivers
6.1.1 Remission and The Chance of Recurrence
6.1.2 Increasing Public Awareness
6.2 Market Restraints
6.2.1 Small Patient Pool
6.2.2 Stringent Regulatory Guidelines
6.3 Market Opportunities
6.4 Key Challenges
7. Global Retinoblastoma Treatment Market - Segmentation
7.1 BY TYPE OF TREATMENT
7.1.2 Radiation therapy
7.1.7 High-Dose Chemotherapy and Stem Cell Transplant
8. Global Retinoblastoma Treatment Market - Regional Shares and Forecast
8.1 North America
8.1.1 United States
8.2.5 Spain & Portugal
8.2.8 Rest of Europe
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 The Middle East and Africa
8.4.2 South Africa
8.4.3 Rest of the Middle East and Africa
8.5 Latin America
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.2 Bristol-Myers Squibb
10.4 Spectrum Pharmaceuticals
10.7 Icon Bioscience
10.9 RXi Pharmaceuticals
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market